FDA Accepts BMY's Mezigdomide NDA for Multiple Myeloma

What happened

Bristol Myers Squibb announced the FDA has accepted its New Drug Application for mezigdomide in relapsed/refractory multiple myeloma, a positive regulatory step for the company's pipeline. However, the DeepValue master report maintains a WAIT rating, emphasizing that the investment thesis hinges on 2026 execution—specifically Eliquis growth sustaining +10-15% while gross margin holds 69-70%—rather than early-stage pipeline events. The mezigdomide NDA acceptance is incremental for the growth portfolio but does not alter the near-term policy risks from IRA pricing and Revlimid erosion beginning January 31, 2026. Until Q1-Q2 2026 prints confirm margin stability, the stock remains a show-me story, not a re-rating catalyst.

Implication

The NDA adds to pipeline optionality but is early-stage; investors should wait for Q1-Q2 2026 results to validate gross margin and Eliquis growth before adding positions.

Thesis delta

The mezigdomide NDA acceptance is a modest positive for the growth portfolio narrative, but it does not shift the core thesis: BMY remains a WAIT until Q2 2026 confirms that Eliquis volume growth can absorb IRA price cuts without margin deterioration. The filing does not change the probability-weighted base case of $65 or the bear case of $52, as the bridge-year economics remain policy-fragile and untested.